Medizinportal Arztsuche Apothekensuche KliniksucheHealth Provider Directory - Health in Germany - english-language-version
Home DocSearch ClinicSearch HealthSites

News

2004-11-30:
Unique Cancer Drug Avastin Now Shown to Improve Survival Across Different Metastatic Colorectal Cancer Regimens
Basel, Switzerland, November 30 ( PRN/ots ) - Roche and Genentech, Inc., announced today that Avastin( TM ) ( bevacizumab, rhuMAb - VEGF ), a new innovative anti - angiogenesis drug, has shown for the first time that it significantly increases survival in patients with metastatic colorectal cancer when used in combination (...)
2009-09-21:
Roche to Present New Survival Data From Phase II, III and IV Studies for Avastin, Herceptin and Xeloda
Basel, Switzerland ( PRN/ots ) - - Nearly 150 Abstracts Covering New Tumour Types, New Patient Groups and Existing Indications to Feature in ECCO - ESMO Program Roche will present encouraging results from nearly 150 scientific studies investigating use of its major cancer medicines at (...)
2005-12-14:
EU Committee for Orphan Medicinal Products Recommends Orphan Drug Designation for ZD6474 ( ZACTIMA[TM] ) for the Investigation of a Rare Form of Thyroid Cancer
Alderley Park, England ( PRN/ots ) - AstraZeneca announced today that it has received positive opinion from the Committee for Orphan Medicinal Products ( COMP ) recommending orphan drug designation for ZD6474 ( ZACTIMA( TM ) ) for the treatment of patients with medullary thyroid cancer in the European Union ( EU ). Final (...)
2007-05-11:
Intervet's Bird Flu Vaccine Receives EU License
Boxmeer, The Netherlands ( PRN/ots ) - Intervet, a leading animal health company, received approval for its bird flu ( avian influenza ) vaccine Nobilis( R ) Influenza H7N1. As a result, Europe now has a licensed vaccine to protect birds against the H7 field strain. Last year the European (...)
2010-09-20:
24 - Week Phase 3 Study Found Investigational Drug Dapagliflozin Improved Glycosylated Hemoglobin ( HbA1c ) When Added to Glimepiride in Adults With Type 2 Diabetes Mellitus
Stockholm ( PRN/ots ) - Bristol - Myers Squibb Company ( http://www.bms.com ) and AstraZeneca ( http://www.astrazeneca - us.com ) today announced results from a randomized, double blind Phase 3 clinical study, which demonstrated that the addition of the investigational drug dapagliflozin to existing glimepiride ( sulphonylurea ) therapy produced significant reductions in glycosylated (...)
2005-03-04:
Study Finds Seroquel Effective And Well Tolerated In Elderly Patients With Alzheimer's Disease
Alderley Park, UK ( na Originaltextservice ) - AstraZeneca announced results from a study involving elderly patients with Alzheimer's disease ( AD ) treated with the atypical antipsychotic SEROQUEL ( quetiapine ) today at the annual meeting of the American Association of Geriatric Psychiatry in San Diego, USA. The study found that (...)
2006-02-14:
Orthogen AG: New Osteoarthritis Therapy Approved in the EU
Dusseldorf ( na Originaltextservice ) - After the successful completion of clinical studies, the German biotech company Orthogen AG ( Düsseldorf ) intends to build up a Europe - wide distribution of Orthokine( R ). Orthokine( R ) is a medical device for the production of autologous conditioned serum; containing anti - inflammatory cytokine antagonists (...)
2009-09-15:
Wyeth Presents Data from Five - Year Vertebral Fracture Prevention Study with Bazedoxifene
Collegeville, Pennsylvania ( PRN/ots ) - Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ), announces findings from a placebo - controlled Phase 3 study of bazedoxifene 20 mg extended to five years, which indicated a significant reduction versus placebo in new vertebral fractures in postmenopausal (...)
2010-12-15:
Agendia Publishes Compelling First Independent Validation Study of Colon Cancer Recurrence Test "ColoPrint" in Journal of Clinical Oncology
Irvine, California and Amsterdam ( PRN/ots ) - Agendia, a world leader in molecular cancer diagnostics, announced today that together with principal investigators from Spain, the UK, and the Netherlands, it has published the first independent validation study of its colon cancer recurrence test "ColoPrint" (...)
2008-11-21:
New Biologic Ustekinumab Receives Positive Opinion From European Regulatory Authority for the Treatment of Moderate to Severe Plaque Psoriasis
Beerse, Belgium, November 21 ( PRN/ots ) - Janssen - Cilag announced today that ustekinumab, the first in a new class of biologics, has received a positive opinion for the treatment of moderate to severe plaque psoriasis from the European Committee for Medical Products for Human Use (...)
2005-04-06:
Isotechnika Receives U.S. Patent for Insulin Resistance Diagnostic Test
Edmonton, Canada ( PRN/ots ) - Isotechnika Inc. ( TSX: ISA ) announced today that the Company has been issued U.S. Patent No. 6,878,550 for its diagnostic breath test kit, Diatest( R ). The patent entitled "13C Glucose Breath Test for the Diagnosis of Diabetic Indications and Monitoring Glycemic Control" (...)
2009-09-04:
Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial
Stockholm ( PRN/ots ) - Karolinska Development ( publ ) today announced that one of its portfolio companies, Dilafor AB, has concluded an extensive clinical study of its candidate drug, tafoxiparin, a new drug substance for the prevention of protracted labor during childbirth. The promising results of the (...)
2005-07-25:
Sanofi Pasteur Begins Shipping Adacel( TM ) Vaccine in the US for Combined Protection Against Tetanus, Diphtheria, and Pertussis
Swiftwater, Pennsylvania and Lyon, France ( PRN/ots ) - - First and Only Booster in the US for Protection Against Pertussis From Adolescence Through Adulthood Sanofi Pasteur, the vaccines business of the sanofi - aventis Group ( EURONEXT: SAN ), ( NYSE: SNY ), announces the availability of Adacel( TM ) ( Tetanus (...)
2004-08-31:
Data on Thelin Presented at the European Society of Cardiology Annual Congress
Houston ( PRN/ots ) - - Abstract Presented on Extension Data From STRIDE - 1 Trial in Pulmonary Arterial Hypertension Encysive Pharmaceuticals ( Nasdaq: ENCY ) today announced the presentation of data from a clinical study of Thelin( TM ) ( sitaxsentan ) in pulmonary arterial hypertension ( PAH ), at the European Society of (...)
2008-08-25:
Phase 1b/2a Program Commences for RVX - 208
Calgary, Canada ( PRN/ots ) - Resverlogix Corp. ( "Resverlogix" or the "Company" ) ( TSX: RVX ) is pleased to announce that the Phase 1b/2a program for the study of RVX - 208 in subjects with normal lipids and those with low high - density lipoprotein ( HDL ) cholesterol has proceeded (...)
2011-02-23:
Agendia Receives Fifth FDA Clearance for Industry Leading MammaPrint( R ) Assay
Irvine, California and Amsterdam ( PRN/ots ) - Agendia, a world leader in molecular cancer diagnostics, today announced that the company has received its fifth U.S. Food and Drug Administration ( FDA ) clearance for MammaPrint( R ), its widely used breast cancer recurrence assay. The new clearance is (...)
2009-05-07:
AMT Starts Preregistration Trial for Glybera( TM )
Amsterdam ( PRN/ots ) - Amsterdam Molecular Therapeutics ( Euronext: AMT ), a leader in the field of human gene therapy, announced today the treatment of the first patient in a preregistration clinical trial with Glybera( TM ). This gene therapy product targets lipoprotein lipase deficiency ( LPLD ), a seriously debilitating and (...)
2007-11-06:
Fenofibrate - First Lipid Modifying Agent Shown to Protect Diabetic Eye
Sydney, November 6 ( PRN/ots ) - - First Lipid Modifying Agent Shown to Reduce Risk of Leading Causes of Blindness and Deteriorating Vision in Patients With Type 2 Diabetes - Reduces Need for Laser Treatment in Patients With and Without Known Diabetic Retinopathy - Significantly Decreases (...)
2009-04-20:
Newly Published Study Shows That Re - Treatment With Pegasys( R ) ( Peginterferon Alfa - 2a ) Provides Hepatitis C Patients With a Second Chance for a Cure
Basel, Switzerland ( PRN/ots ) - New data published today in a major peer - reviewed journal, Annals of Internal Medicine, show that re - treatment with Pegasys( R ) ( peginterferon alfa - 2a ) plus Copegus( R ) ( ribavirin ) provides previously - treated hepatitis C patients a second chance for a cure. The study (...)
2007-09-26:
New Phase III Data Demonstrate Oxycodone / Naloxone Combination Tablet Reduces Opioid - Induced Bowel Dysfunction in Patients With Chronic Severe Pain
Cambridge, England ( PRN/ots ) - - New Approach in the Development of Opioid - Based Pain Management Therapy Improves Bowel Function The oral prolonged - release ( PR ) oxycodone / naloxone combination tablet reduces opioid - induced bowel dysfunction in patients with chronic severe pain compared to treatment with (...)
2010-12-08:
Edoxaban Demonstrates Superior Efficacy Compared With Enoxaparin Sodium in Preventing VTE After Total Hip Replacement
Tokyo ( PRN/ots ) - Daiichi Sankyo Company, Limited announced that its investigational once - daily oral, direct factor Xa inhibitor, edoxaban, was shown to be superior to enoxaparin sodium in preventing venous thromboembolic ( VTE ) events in patients following total hip replacement ( THR ), a type of major (...)
2004-12-06:
New Data Show Cialis( R ) ( tadalafil ) May Effectively Treat ED in Men With Clinical Depression, Diabetes and Traumatic Spinal Cord Injuries
London ( PRN/ots ) - - Patients with moderate - to - severe ED and comorbid conditions respond to Cialis Cialis( R )( 1 ) ( tadalafil ) may effectively treat erectile dysfunction ( ED ) in men with a variety of comorbidities that can make the condition more difficult to manage, according to new (...) ( 1 ) Cialis( R ) is a registered trademark of Lilly ICOS LLC. All other trademarks are the property of their respective owners. ( 2 ) The Sexual Encounter Profile, SEP, is a patient self - administered diary completed by clinical trial participants after each sexual encounter. ( 3 ) The International Index of Erectile Function, IIEF, is an international scale that assesses erectile function in cross - cultural settings by measuring treatment - related responses in patients. ( 4 ) The Global Assessment Questionnaire, GAQ, is a self - administered questionnaire that allows patients to rate improvement in erectile function. ( 5 ) SEP 3 - "Did your erection last long enough for you to successfully complete intercourse?" ( 6 ) SEP 2 - "Were you able to achieve an erection sufficient to achieve penetration with your partner?" ( 7 ) Data were extrapolated from Feldman HA, Goldstein I, Hatzichistou DG, Krane RJ. Impotence and its Medical and Psychosocial Correlates: Results of the Massachusetts Male Aging Study, Journal of Urology. Vol 151, 54 - 61, January 1994 and World Population Projection Program of United Nations ( 2002 Revisions ) with indirect standardization. ( 8 ) Shabsigh R ( 2002 ). Back to Great Sex: Overcome ED and Reclaim Lost Intimacy. New York: Kensington. ( 9 ) Diseases and Conditions: Impotence, http://www.impotence.org/FAQ/index.asp . Data accessed 11.20.03 ( 10 ) Lue, Tom F. Erectile Dysfunction. N Engl J Med 2000; 342: 1802 - 1813. ( Logo: http://www.newscom.com/cgi - bin/prnh/20040122/LILLYICOSLOGO ) ots Originaltext: Lilly ICOS LLC Im Internet recherchierbar: http://www.presseportal.de Contact: Jane Calloway of Lilly, +1 - 317 - 651 - 5870; or Lacy Fitzpatrick of ICOS, +1 - 425 - 415 - 2207/Photo: http://www.newscom.com/cgi - bin/prnh/20040122/LILLYICOSLOGO, PRN Photo Desk, photodesk@prnewswire.com/
2004-09-08:
Thelin May Offer Alternative for PAH Patients Who Have Failed on Bosentan, According to Data Presented at European Respiratory Society Congress
Houston ( PRN/ots ) - - Study Shows Liver Toxicities Experienced by Patients on Bosentan Were Not Experienced on Thelin Encysive Pharmaceuticals ( Nasdaq: ENCY ) today announced the presentation of new clinical data on Thelin( TM ) ( sitaxsentan ) in pulmonary arterial hypertension ( PAH ), at the European Respiratory Society ( ERS ) (...)
2010-07-12:
Edoxaban Demonstrates Superior Efficacy Compared With Enoxaparin Sodium in Preventing VTE After Total Knee Replacement
Tokyo, July 12, 2010 ( PRN/ots ) - Daiichi Sankyo Company, Limited announced that its investigational once - daily oral, direct factor Xa inhibitor, edoxaban, was shown to be superior to enoxaparin in preventing venous thromboembolic ( VTE ) events in patients following total knee replacement ( TKR ), a type (...)
2005-05-11:
Genizon Biosciences Acquires Assets from Global Genomics to Accelerate the Discovery of Disease - Causing Mutations and Targets
Montreal, Canada ( PRN/ots ) - Genizon BioSciences, Inc., a Montreal - based gene and drug target discovery company, announced today it has acquired the majority of the assets and staff of Sweden - based Global Genomics AB. Through this transaction, Genizon has gained access to a novel (...)
2007-05-06:
Protelos( R ): First Osteoporosis Treatment to Show Long - Term, Sustained Efficacy and Quality of Life Improvement
Copenhagen, Denmark ( PRN/ots ) - - New Data Show Clear Benefit of Protelos( R ) in Wide Range of Osteoporosis Patients Irrespective of Disease Severity New, long term data presented at the 34th European Symposium on Calcified Tissues ( ECTS ) this week underscore the unmatchable, long - term (...)
2005-11-17:
Experts Call for Re - Focussing of COPD Management to Reduce Hospital Admissions and Mortality
Lund, Switzerland, November 17 ( PRN/ots ) - For Non - US Medical Journalists Only A new report on the importance of treating Chronic Obstructive Pulmonary Disease ( COPD ) exacerbations is launched today, on World COPD Day. Global dissemination of the report to family physicians/General Practitioners around (...)
2005-11-14:
The role of pharmaceutical wholesaling in the safe provision of medicines - Exclusive preview of recent study
Brussels ( na Originaltextservice ) - PRESS CONFERENCE 22nd November 2005, 10.30 am Hotel Silken Berlaymont ( Room Gasperi 3 ) Boulevard Charlemagne 11 - 19 B - 1000 Brussels Have you ever thought about how medicines reach patients in Europe and how all medicines are readily (...)
2004-10-19:
Men with Erectile Dysfunction Cite Reduction in Time Pressure to Perform and Increased Sexual Self - Confidence As Preference Points for Cialis
Buenos Aires, Argentina ( PRN/ots ) - - - Additional Analysis Shows Couples Agree Cialis Improves Erectile Function in Men with ED and Increases Satisfaction with Sexual Experience - - An international study conducted in 21 countries showed that 82 percent of men with ED who were (...)
2007-08-29:
American Stock Exchange Accepts Callisto Pharamceuticals' Plan of Compliance and Extension to Regain Compliance with Standards
New York ( PRN/ots ) - Callisto Pharmaceuticals, Inc. ( Amex: KAL; FWB: CA4 ), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders and diseases, today announced that the staff of the American Stock Exchange ( "AMEX" ) has reviewed the Company's plan (...)
2009-07-20:
Head - to - Head Trial Demonstrates Viramune( R )'s Similar Efficacy and Superior Effect on Lipid Profile Compared to atazanavir/ritonavir
Cape Town, South Africa ( PRN/ots ) - - For Medical Media Outside the US Only Results from the ARTEN* trial presented at the 5th International AIDS Society ( IAS ) conference in Cape Town, South Africa demonstrated non - inferiority regarding efficacy between Viramune( R ) ( nevirapine ) and ritonavir (...)
2006-03-15:
Degussa BioRenewables Days / Renewable raw materials as alternatives to petrochemicals
Dusseldorf ( na Originaltextservice ) - The chemical industry already meets up to 8 percent of its demand for starting materials with renewable raw materials. Strategies for gaining a further increase in this share, and the technological tools that need to be developed for this purpose, are the (...)
2009-05-29:
New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER - 2 Positive Breast Cancer
Collegeville, Pennsylvania ( PRN/ots ) - Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ), today announced preliminary data from two ongoing studies, one evaluating neratinib ( HKI - 272 ) in combination with trastuzumab ( Herceptin( R ), Roche ) in HER - 2 positive ( ErbB - 2 positive ) breast cancer, and a separate (...)
2006-10-31:
Boehringer Ingelheim's Pramipexole ( Mirapexin( R )/Sifrol( R ) ) Shown to Improve Depressive and Motivational Symptoms in Parkinson's Disease
Kyoto, Japan ( PRN/ots ) - - Further Therapeutic Potential of Pramipexole to be Investigated in New Disease - Modification Trial - For non - US Healthcare Media New data presented today from a meta - analysis* of nearly 1,300 Parkinson's disease ( PD ) patients indicate that pramipexole ( Mirapexin( R ) /Sifrol( R ) ) (...)
2011-04-15:
Study Suggests up to 135,000 Lives Could be Saved in Europe Each Year Through Better Control of Cardiovascular Risk Factors
Geneva ( PRN/ots ) - Results from a large pan - European study suggest that up to 135,000 deaths from cardiovascular disease ( CVD ), such as heart attacks and strokes, could be prevented in Europe each year though better control of risk factors including high blood pressure, high (...)
2007-03-30:
Xeloda Approved in Europe for the Treatment of Advanced Stomach Cancer
Basel, Switzerland ( PRN/ots ) - - New Oral Treatment Option Reduces Time in Hospital by 80 Prozent - For Non - US Media Only The European Commission has approved Xeloda in combination with platinum - based chemotherapy, for first - line use in patients with advanced stomach cancer. (...)
2010-10-20:
Takeda Submits European Marketing Authorisation Application for Azilsartan Medoxomil, an Investigational Compound for the Treatment of Essential Hypertension
London and Osaka, Japan ( PRN/ots ) - Takeda Pharmaceutical Company Limited ( Takeda ) today announced that Takeda Global Research & Development Centre ( Europe ), Ltd. submitted a Marketing Authorisation Application ( MAA ) for azilsartan medoxomil ( development code: TAK - 491 ), an angiotensin II receptor blocker ( ARB ), to the European Medicines (...)
2004-11-01:
Boehringer Ingelheim Announces 24 - Week Interim Results from Tipranavir RESIST - 1 Phase 3 Study
Washington, November 1 ( PRN/ots ) - New data from a pivotal Phase 3 study ( RESIST - 1 ) demonstrate that a statistically significant greater percentage of HIV - positive patients taking a tipranavir - based regimen achieved a treatment response versus those taking a regimen containing one of several (...)
2011-03-30:
Astellas and Medivation Announce Initiation of Phase 2 Clinical Trial Comparing MDV3100 With Bicalutamide in Advanced Prostate Cancer
LONDON, STAINES, England and SAN FRANCISCO, March 30, 2011 ( PRN/ots ) - - Astellas Pharma Europe Ltd. and Medivation, Inc. today announced treatment of the first patient in the TERRAIN trial, a Phase 2 comparison of the investigational drug MDV3100, a triple - acting, oral androgen receptor (...)
2009-08-31:
Abbott Launches Next - Generation XIENCE PRIME( TM ) Drug Eluting Stent in International Markets
Barcelona, Spain ( PRN/ots ) - - New Cobalt Chromium Stent Offers Enhanced Deliverability with a Broad Matrix of Sizes - Built Upon the Proven Track Record of Superior Clinical Outcomes of Abbott's Market - Leading XIENCE V( R ) Drug Eluting Stent Abbott ( NYSE: ABT ) today announced (...)
2007-03-26:
Enzastaurin Granted Orphan Drug Status for Treatment of Diffuse Large B - Cell Lymphoma ( DLBCL )
Indianapolis ( PRN/ots ) - - Oral Agent Designed to Address High Incidence of Relapse in DLBCL Population Eli Lilly and Company announced today that the European Medicines Agency ( EMEA ) has granted enzastaurin, an investigational, multi - targeted, oral, cancer agent, orphan drug designation for the treatment (...)
2010-02-16:
Abbott Completes Acquisition of Solvay Pharmaceuticals
Abbott Park, Illinois, February 16, 2010 ( PRN/ots ) - Abbott today announced that it has completed its EUR 4.5 billion ( US$6.2 billion ) acquisition of Belgium - based Solvay Pharmaceuticals, providing Abbott with a large and complementary portfolio of pharmaceutical products and expanding Abbott's presence in key (...)
2007-04-23:
MIRCERA( R ) Effective in Stabilising Haemoglobin Levels in Elderly Patients With Kidney Disease on Dialysis
Basel, Switzerland ( PRN/ots ) - - Findings Illustrate Role of Innovative New Treatment in Population Most Affected by Chronic Kidney Disease A new Roche Phase III analysis shows once - monthly MIRCERA, a continuous erythropoietin receptor activator, effectively treats renal anaemia in one of the (...)
2009-09-01:
Edoxaban - next generation oral anticoagulant under investigation to help prevent stroke in patients with atrial fibrillation
Barcelona ( na Originaltextservice ) - New treatment could offer further option in addition to current standard of care in thromboembolic disease Edoxaban, an oral factor Xa inhibitor, is currently being investigated in the pivotal phase III study ENGAGE AF - TIMI 48 ( Effective aNticoaGulation (...)
2009-07-06:
New Small and Medium Sized Enterprises Join TI Pharma by Signing Two New Projects
Leiden, The Netherlands ( PRN/ots ) - Three new small and medium sized enterprises ( SMEs ) - Syncom, Synvolux Therapeutics and InteRNA Technologies - have joined public - private partnership TI Pharma by participating in two new projects. These projects, focusing on cancer and inflammatory diseases, have a total budget (...)
2006-09-19:
Sanofi pasteur Broadens Pandemic Preparedness With First Clinical Trial of Novel Cell Based H7N1 Vaccine
Lyon, France ( PRN/ots ) - Sanofi pasteur, the vaccines business of the sanofi - aventis Group, has within the framework of FLUPAN, a collaborative research project funded by the European Commission, generated the first clinical trial lot of a new generation of H7N1 pandemic vaccine. This (...)
2005-03-23:
BioWa, Inc. Licenses Anti IL - 5 Receptor Antibody from Kyowa Hakko Kogyo Co., Ltd.
Princeton, New Jersey ( PRN/ots ) - BioWa announced today that it has successfully licensed from Kyowa Hakko Kogyo Co., Ltd. ( Tokyo, Osaka, Nagoya, Fukuoka, Sapporo: 4151 ), its parent company, the exclusive worldwide rights, except Asia, to develop and commercialize anti IL - 5 receptor antibody, a (...)
2007-05-24:
Workplace Burden of Depression Magnified by Co - morbid Fatigue and Anxiety, New Study Shows
San Diego ( PRN/ots ) - Depression, well known to reduce workplace productivity, causes significantly greater productivity declines when accompanied by common co - occurring conditions such as fatigue, sleep problems or anxiety, according to a large new study presented today at the American Psychiatric Association's (...)
2010-03-24:
Agendia Launches BluePrint( TM ) Expanding Breast Cancer Product Offering
HUNTINGTON BEACH, California and AMSTERDAM, March 24, 2010 ( PRN/ots ) - - Agendia, a world leader in molecular cancer diagnostics, today announced that its breast cancer product offering, consisting of breast cancer recurrence test MammaPrint( R ), and TargetPrint( TM ), has been expanded with BluePrint ( TM ) to report important additional (...)

back... 1 2 3 4 5 6 7 8 9 10 11 more...



» German Health-Sites

Medical and health related Websites from Germany

Alternative Medicine
Beauty and Wellness
Manufacturers of Medical Equipment
Biotechnology
International
Databases
German Doctors Worldwide
German Medicine and Patient Transfer
Special Diagnoses
Acne
Cancer
Diabetes
Nutrition and Diet
Family
Fitness and Sports
Forums
Womens Health
Genetics
Health-Marketing
Dating
Health Insurance
Other Insurances
Literature and Publishers
Newspaper / Magazines
Organizations
Care
Portals and Directories
Pharmacies
Portals and Directories Dental Medicine
Search
Psyche
Public Health
Governmental Links
Guides
Regional
Baden-Wuerttemberg
Bavaria
Berlin
North Rhine-Westphalia
Travel Medicine
Self-Help
AIDS
Alcoholism
Alzheimer
Medical malpractice
Visually Impaired
Seminar
Seniors / 50+
Seniors / Living
Shopping
Medical Technology
Children-, Youth- and Social Work
Scholastics
Accommodation
Organization
Mixed


© 2003-2008 med-kolleg.de Health Provider Directory
Clinics and Physicians
Berlin, Germany Samstag, 20.10.2018.
Sitemap (Sitemap German) Imprint Press (German)
Ärzteverzeichnis Klinikverzeichnis Apothekenverzeichnis Ärztesuche
 Fri, 19 Oct 2018 12:17:23 GMT
Werben im Gesundheitssektor / Medizin

Health Provider Directory

Medizin und Gesundheit - Arztsuche Kliniksuche Apothekensuche
Gesundheitsportal